Literature DB >> 29181304

DNA vaccine expressing herpes simplex virus 1 glycoprotein C and D protects mice against herpes simplex keratitis.

Li-Li Dong1,2,3, Ru Tang3,4, Yu-Jia Zhai3, Tejsu Malla3, Kai Hu1,5.   

Abstract

AIM: To investigate whether DNA vaccine encoding herpes simplex virus 1 (HSV-1) glycoprotein C (gC) and glycoprotein D (gD) will achieve better protective effect against herpes simplex keratitis (HSK) than DNA vaccine encoding gD alone.
METHODS: DNA vaccine expressing gD or gC combined gD (gD.gC) were constructed and carried by chitosan nanoparticle. The expression of fusion protein gD and gC were detected in DNA/nanoparticle transfected 293T cells by Western-blot. For immunization, mice were inoculated with DNA/nanoparticle for 3 times with 2wk interval, and two weeks after the final immunization, the specific immune responses and clinical degrees of primary HSK were evaluated.
RESULTS: Fusion protein gD.gC could be expressed successfully in cultured 293T cells. And, pRSC-gC.gD-IL21 DNA/chitosan nanoparticle could effectively elicit strongest humoral and cellular immune response in primary HSK mice evidenced by higher levels of specific neutralizing antibody and sIgA production, enhanced cytotoxicities of splenocytes and nature killer cells (NK), when compared with those of gD alone or mocked vaccine immunized mice. As a result, gC-based vaccine immunized mice showed least HSK disease.
CONCLUSION: gC-based DNA vaccine could effectively prevent the progress of primary HSK, suggesting that this DNA vaccine could be a promising vaccine for HSK treatment in the future.

Entities:  

Keywords:  gC-based DNA vaccine; herpes simplex virus 1; immune response; keratitis; nanocarrier

Year:  2017        PMID: 29181304      PMCID: PMC5686359          DOI: 10.18240/ijo.2017.11.01

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN: 2222-3959            Impact factor:   1.779


  32 in total

Review 1.  Potential of nanocarriers in genetic immunization.

Authors:  Kapil Khatri; Amit K Goyal; Suresh P Vyas
Journal:  Recent Pat Drug Deliv Formul       Date:  2008

Review 2.  Nasal delivery of vaccines.

Authors:  A J Almeida; H O Alpar
Journal:  J Drug Target       Date:  1996       Impact factor: 5.121

Review 3.  Using Plasmids as DNA Vaccines for Infectious Diseases.

Authors:  John S Tregoning; Ekaterina Kinnear
Journal:  Microbiol Spectr       Date:  2014-12

4.  Immunization with DNA vaccine expressing herpes simplex virus type 1 gD and IL-21 protects against mouse herpes keratitis.

Authors:  Kai Hu; Xiangfeng He; Fangliu Yu; Xianwen Yuan; Weihua Hu; Chunsheng Liu; Fengshu Zhao; Jun Dou
Journal:  Immunol Invest       Date:  2011-01-04       Impact factor: 3.657

5.  Immune evasion properties of herpes simplex virus type 1 glycoprotein gC.

Authors:  H M Friedman; L Wang; N O Fishman; J D Lambris; R J Eisenberg; G H Cohen; J Lubinski
Journal:  J Virol       Date:  1996-07       Impact factor: 5.103

6.  Complement component C3b binds directly to purified glycoprotein C of herpes simplex virus types 1 and 2.

Authors:  R J Eisenberg; M Ponce de Leon; H M Friedman; L F Fries; M M Frank; J C Hastings; G H Cohen
Journal:  Microb Pathog       Date:  1987-12       Impact factor: 3.738

7.  Immunization with HSV-1 glycoprotein C prevents immune evasion from complement and enhances the efficacy of an HSV-1 glycoprotein D subunit vaccine.

Authors:  Sita Awasthi; John M Lubinski; Harvey M Friedman
Journal:  Vaccine       Date:  2009-09-15       Impact factor: 3.641

8.  Immune evasion by herpes simplex virus type 1, strategies for virus survival.

Authors:  Harvey M Friedman
Journal:  Trans Am Clin Climatol Assoc       Date:  2003

Review 9.  Herpes keratitis.

Authors:  A M Rowe; A J St Leger; S Jeon; D K Dhaliwal; J E Knickelbein; R L Hendricks
Journal:  Prog Retin Eye Res       Date:  2012-08-27       Impact factor: 21.198

Review 10.  Molecular gymnastics at the herpesvirus surface.

Authors:  Félix A Rey
Journal:  EMBO Rep       Date:  2006-10       Impact factor: 8.807

View more
  2 in total

Review 1.  Programmed Cell Death-Dependent Host Defense in Ocular Herpes Simplex Virus Infection.

Authors:  Hongyan Guo; Heather S Koehler; Richard D Dix; Edward S Mocarski
Journal:  Front Microbiol       Date:  2022-04-08       Impact factor: 5.640

Review 2.  Ocular manifestations of herpes simplex virus.

Authors:  Gabriel S Valerio; Charles C Lin
Journal:  Curr Opin Ophthalmol       Date:  2019-11       Impact factor: 3.761

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.